A Novel Bruton's Tyrosine Kinase Inhibitor CC-292 In Combination With The Proteasome Inhibitor Carfilzomib Iimpacts Multiple Myeloma Bone Microenviroment With Resultant Anti-Myeloma Activity

被引：0
|
作者：
Eda, Homare
Santo, Loredana
Cirstea, Diana D.
Yee, Andrew J.
Scullen, Tyler A.
Nemani, Neeharika
Mishima, Yuko
Arastu-Kapur, Shirin
Evans, Erica
Singh, Juswinder
Kirk, Christopher J.
Westlin, William F.
Raje, Noopur S.
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.682.682
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
682
引用
收藏
页数：2
相关论文
共 42 条
  • [1] A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity
    Eda, H.
    Santo, L.
    Cirstea, D. D.
    Yee, A. J.
    Scullen, T. A.
    Nemani, N.
    Mishima, Y.
    Waterman, P. R.
    Arastu-Kapur, S.
    Evans, E.
    Singh, J.
    Kirk, C. J.
    Westlin, W. F.
    Raje, N. S.
    LEUKEMIA, 2014, 28 (09) : 1892 - 1901
  • [2] A novel Bruton’s tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity
    H Eda
    L Santo
    D D Cirstea
    A J Yee
    T A Scullen
    N Nemani
    Y Mishima
    P R Waterman
    S Arastu-Kapur
    E Evans
    J Singh
    C J Kirk
    W F Westlin
    N S Raje
    Leukemia, 2014, 28 : 1892 - 1901
  • [3] CC-292, A NOVEL BRUTON'S TYROSINE KINASE INHIBITOR ALONE AND IN COMBINATION WITH CARFILZOMIB IMPACTS BONE RESORPTION IN MULTIPLE MYELOMA BY BLOCKING OSTEOCLAST SEALING ZONE FORMATION
    Eda, H.
    Loredana, S.
    Cirstea, D.
    Yee, A.
    Mahindra, A.
    Scullen, T.
    Nemani, N.
    Mishima, Y.
    Kapur, S.
    Evans, E.
    Singh, J.
    Kirke, C.
    Westlin, W.
    Raje, N.
    HAEMATOLOGICA, 2013, 98 : 227 - 228
  • [4] Prevention of Bone Destruction by Mechanical Loading Is Not Enhanced by the Bruton's Tyrosine Kinase Inhibitor CC-292 in Myeloma Bone Disease
    Ziouti, Fani
    Rummler, Maximilian
    Steyn, Beatrice
    Thiele, Tobias
    Seliger, Anne
    Duda, Georg N.
    Bogen, Bjarne
    Willie, Bettina M.
    Jundt, Franziska
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (08)
  • [5] TYROSINE KINASE INHIBITORS POTENTIATE ANTI-MYELOMA ACTIVITY OF PROTEASOME INHIBITOR CARFILZOMIB IN RESISTANT MULTIPLE MYELOMA CELL LINES AND PATIENT SAMPLES
    Ao, Lin
    Lee, Wooin
    Kim, Kyung-Bo
    DRUG METABOLISM AND PHARMACOKINETICS, 2017, 32 (01) : S50 - S50
  • [6] A Chemoproteomics Approach to Determine the Mechanism of Testicular Toxicity for the Bruton's Tyrosine Kinase Inhibitor CC-292
    Labenski, Matt
    Voortman, Lukas
    Medikonda, Aravind Prasad
    Sherratt, Philip J.
    Corin, Alan F.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2021, 379 (02): : 166 - 174
  • [7] PRECLINICAL ACTIVITY OF NOVEL BRUTON'S TYROSINE KINASE INHIBITOR ARQ531 ON MULTIPLE MYELOMA CELLS
    Retali, V.
    Soncini, D.
    Minetto, P.
    Ruberti, S.
    Contini, P.
    Rivoli, G.
    Bisso, N.
    Di Felice, N.
    Cagnetta, A.
    Eathiraj, S.
    Abbadessa, G.
    Schwartz, B.
    Gobbi, M.
    Lemoli, R. M.
    Cea, M.
    HAEMATOLOGICA, 2018, 103 : S114 - S114
  • [8] A novel dual inhibitor of microtubule and Bruton's tyrosine kinase inhibits survival of multiple myeloma and osteoclastogenesis
    Pandey, Manoj K.
    Gowda, Krishne
    Sung, Shen-shu
    Abraham, Thomas
    Budak-Alpdogan, Tulin
    Talamo, Giampolo
    Dovat, Sinisa
    Amin, Shantu
    EXPERIMENTAL HEMATOLOGY, 2017, 53 : 31 - 42
  • [9] Isatin analog as bruton tyrosine kinase inhibitor: A promising novel agent for multiple myeloma treatment
    Gowda, Krishne
    Pandey, Manoj K.
    Sharma, Arun K.
    Amin, Shantu
    CANCER RESEARCH, 2014, 74 (19)
  • [10] MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity
    Saha, Manujendra N.
    Jiang, Hua
    Jayakar, Jennifer
    Reece, Donna
    Branch, Donald R.
    Chang, Hong
    CANCER BIOLOGY & THERAPY, 2010, 9 (11) : 936 - 944
12345